Skip to main content
Top
Published in: Trials 1/2016

Open Access 01-12-2016 | Study protocol

Dementia and Physical Activity (DAPA) - an exercise intervention to improve cognition in people with mild to moderate dementia: study protocol for a randomized controlled trial

Authors: Nicky Atherton, Chris Bridle, Deborah Brown, Helen Collins, Sukhdeep Dosanjh, Frances Griffiths, Susie Hennings, Kamran Khan, Ranjit Lall, Samantha Lyle, Rupert McShane, Dipesh Mistry, Vivien Nichols, Stavros Petrou, Bart Sheehan, Anne-Marie Slowther, Margaret Thorogood, Emma Withers, Peter Zeh, Sarah E. Lamb

Published in: Trials | Issue 1/2016

Login to get access

Abstract

Background

Dementia is more common in older than in younger people, and as a result of the ageing of the population in developed countries, it is becoming more prevalent. Drug treatments for dementia are limited, and the main support offered to people with dementia and their families is generally services to mitigate against loss of function. Physical exercise is a candidate non-pharmacological treatment for dementia.

Methods/Design

DAPA is a randomised controlled trial funded by the National Institute for Health Research Health Technology Assessment programme to estimate the effect of a 4-month, moderate- to hard-intensity exercise training programme and subsequent advice to remain active, on cognition (primary outcome) at 12 months in people with mild to moderate dementia. Community-dwelling participants (with their carers where possible), who are able to walk 3 metres without human assistance, able to undertake an exercise programme and do not have any unstable or terminal illness are recruited. Participants are then randomised by an independent statistician using a computerised random number generator to usual care or exercise at a 2:1 ratio in favour of exercise. The exercise intervention comprises 29, 1-hour-long exercise classes, run twice weekly at suitable venues such as leisure centres, which include aerobic exercise (on static bikes) and resistance exercise (using weights). Goals for independent exercise are set while the classes are still running, and supported thereafter with phone calls.
The primary outcome is measured using ADAS-cog. Secondary outcome measures include behavioural symptoms, functional ability, quality of life and carer burden. Primary and secondary outcomes will be measured at baseline and at 6 and 12 months after randomisation, by researchers masked to participant randomisation in the participants’ own homes. An economic evaluation will be carried out in parallel to the RCT, as will a qualitative study capturing the experiences of participants, carers and staff delivering the intervention.

Discussion

The DAPA study will be the first large, randomised trial of the cognitive effects of exercise on people with dementia. The intervention is designed to be capable of being delivered within the constraints of NHS service provision, and the economic evaluation will allow assessment of its cost-effectiveness.

Trial registration

DAPA was registered with the ISRCTN database on 29 July 2011, registration number ISRCTN32612072.
Literature
2.
go back to reference Rocca WA, Hofman A, Brayne C, Breteler MMB, Clarke M, Copeland JRM, et al. Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol. 1991;30(3):381–90.CrossRefPubMed Rocca WA, Hofman A, Brayne C, Breteler MMB, Clarke M, Copeland JRM, et al. Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol. 1991;30(3):381–90.CrossRefPubMed
3.
go back to reference National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (TA217). London, UK: National Institute for Health and Clinical Excellence; 2011. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (TA217). London, UK: National Institute for Health and Clinical Excellence; 2011.
4.
go back to reference Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2015;4:CD006489.PubMed Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2015;4:CD006489.PubMed
5.
go back to reference Vertesi A, Lever JA, Molloy DW, Sanderson B, Tuttle I, Pokoradi L, et al. Standardized Mini-Mental State Examination. Use and interpretation. Can Fam Physician. 2001;47:2018–23.PubMedPubMedCentral Vertesi A, Lever JA, Molloy DW, Sanderson B, Tuttle I, Pokoradi L, et al. Standardized Mini-Mental State Examination. Use and interpretation. Can Fam Physician. 2001;47:2018–23.PubMedPubMedCentral
6.
go back to reference Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S13–21.CrossRefPubMed Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S13–21.CrossRefPubMed
7.
go back to reference Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ. 2005;331(7512):321–7.CrossRefPubMedPubMedCentral Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ. 2005;331(7512):321–7.CrossRefPubMedPubMedCentral
8.
go back to reference Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing. 1996;25(2):113–20.CrossRefPubMed Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing. 1996;25(2):113–20.CrossRefPubMed
9.
go back to reference Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer’s disease: patient and caregiver reports. J Ment Health Aging. 1999;5:21–32. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer’s disease: patient and caregiver reports. J Ment Health Aging. 1999;5:21–32.
10.
go back to reference EuroQuol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRef EuroQuol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRef
11.
go back to reference Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14.CrossRefPubMed Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14.CrossRefPubMed
12.
go back to reference Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20(6):649–55.CrossRefPubMed Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20(6):649–55.CrossRefPubMed
14.
go back to reference Moniz-Cook E, Vernooij-Dassen M, Woods R, Verhey F, Chattat R, Vugt M, et al. A European consensus on outcome measures for psychosocial intervention research in dementia care. Aging Ment Health. 2008;12(1):14–29.CrossRefPubMed Moniz-Cook E, Vernooij-Dassen M, Woods R, Verhey F, Chattat R, Vugt M, et al. A European consensus on outcome measures for psychosocial intervention research in dementia care. Aging Ment Health. 2008;12(1):14–29.CrossRefPubMed
17.
go back to reference Brown D, Spanjers K, Atherton N, Lowe J, Stonehewer L, Bridle C, et al. Development of an exercise intervention to improve cognition in people with mild to moderate dementia: Dementia And Physical Activity (DAPA) Trial, registration ISRCTN32612072. Physiotherapy. 2015;101(2):126–34.CrossRefPubMed Brown D, Spanjers K, Atherton N, Lowe J, Stonehewer L, Bridle C, et al. Development of an exercise intervention to improve cognition in people with mild to moderate dementia: Dementia And Physical Activity (DAPA) Trial, registration ISRCTN32612072. Physiotherapy. 2015;101(2):126–34.CrossRefPubMed
18.
go back to reference Ries JD, Echternach JL, Nof L, Gagnon Blodgett M. Test-retest reliability and minimal detectable change scores for the timed “up & go” test, the six-minute walk test, and gait speed in people with Alzheimer disease. Phys Ther. 2009;89(6):569–79.CrossRefPubMed Ries JD, Echternach JL, Nof L, Gagnon Blodgett M. Test-retest reliability and minimal detectable change scores for the timed “up & go” test, the six-minute walk test, and gait speed in people with Alzheimer disease. Phys Ther. 2009;89(6):569–79.CrossRefPubMed
19.
go back to reference Borg G. Borg’s perceived exertion and pain scales. Champaign, IL: Human Kinetics; 1998. Borg G. Borg’s perceived exertion and pain scales. Champaign, IL: Human Kinetics; 1998.
20.
go back to reference Yu F, Kolanowski A. Facilitating aerobic exercise training in older adults with Alzheimer’s Disease. Geriatr Nurs. 2009;30(4):250–9.CrossRefPubMed Yu F, Kolanowski A. Facilitating aerobic exercise training in older adults with Alzheimer’s Disease. Geriatr Nurs. 2009;30(4):250–9.CrossRefPubMed
21.
go back to reference Pollock ML, Gaesser GA, Butcher JD, Després J-P, Dishman RK, Franklin BA, et al. ACSM position stand: the recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc. 1998;30(6):975–91.CrossRef Pollock ML, Gaesser GA, Butcher JD, Després J-P, Dishman RK, Franklin BA, et al. ACSM position stand: the recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc. 1998;30(6):975–91.CrossRef
22.
go back to reference Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer’s disease: a European task force consensus. Lancet Neurol. 2008;7(5):436–50.CrossRefPubMed Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer’s disease: a European task force consensus. Lancet Neurol. 2008;7(5):436–50.CrossRefPubMed
23.
go back to reference Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5(33):1–56.CrossRefPubMed Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5(33):1–56.CrossRefPubMed
24.
25.
go back to reference Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300(15):1774–83.CrossRefPubMedPubMedCentral Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300(15):1774–83.CrossRefPubMedPubMedCentral
26.
go back to reference Machin D. Sample size tables for clinical studies. 2nd ed. Oxford: Blackwell Science; 1997. Machin D. Sample size tables for clinical studies. 2nd ed. Oxford: Blackwell Science; 1997.
27.
go back to reference Dunn G. Compliance with treatment allocation. Wiley StatsRef: Statistics Reference Online: John Wiley & Sons, Ltd; 2014. Dunn G. Compliance with treatment allocation. Wiley StatsRef: Statistics Reference Online: John Wiley & Sons, Ltd; 2014.
28.
go back to reference Quentin W, Riedel-Heller SG, Luppa M, Rudolph A, Konig HH. Cost-of-illness studies of dementia: a systematic review focusing on stage dependency of costs. Acta Psychiatr Scand. 2010;121(4):243–59.CrossRefPubMed Quentin W, Riedel-Heller SG, Luppa M, Rudolph A, Konig HH. Cost-of-illness studies of dementia: a systematic review focusing on stage dependency of costs. Acta Psychiatr Scand. 2010;121(4):243–59.CrossRefPubMed
29.
go back to reference Rizzo JA, Friedkin R, Williams CS, Nabors J, Acampora D, Tinetti ME. Health care utilization and costs in a Medicare population by fall status. Med Care. 1998;36(8):1174–88.CrossRefPubMed Rizzo JA, Friedkin R, Williams CS, Nabors J, Acampora D, Tinetti ME. Health care utilization and costs in a Medicare population by fall status. Med Care. 1998;36(8):1174–88.CrossRefPubMed
30.
31.
go back to reference Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316(7133):736–41.CrossRefPubMedPubMedCentral Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316(7133):736–41.CrossRefPubMedPubMedCentral
32.
go back to reference Earnshaw J, Lewis G. NICE guide to the methods of technology appraisal: pharmaceutical industry perspective. Pharmacoeconomics. 2008;26(9):725–7.CrossRefPubMed Earnshaw J, Lewis G. NICE guide to the methods of technology appraisal: pharmaceutical industry perspective. Pharmacoeconomics. 2008;26(9):725–7.CrossRefPubMed
33.
go back to reference Thornicroft G, Brewin C, Wing JK. Royal College of Psychiatrists. Measuring mental health needs. London: Gaskell; 1992. Thornicroft G, Brewin C, Wing JK. Royal College of Psychiatrists. Measuring mental health needs. London: Gaskell; 1992.
34.
go back to reference Lloyd V, Gatherer A, Kalsy S. Conducting qualitative interview research with people with expressive language difficulties. Qual Health Res. 2006;16(10):1386–404.CrossRefPubMed Lloyd V, Gatherer A, Kalsy S. Conducting qualitative interview research with people with expressive language difficulties. Qual Health Res. 2006;16(10):1386–404.CrossRefPubMed
35.
go back to reference Moore TF, Hollett J. Giving voice to persons living with dementia: the researcher’s opportunities and challenges. Nurs Sci Q. 2003;16(2):163–7.CrossRefPubMed Moore TF, Hollett J. Giving voice to persons living with dementia: the researcher’s opportunities and challenges. Nurs Sci Q. 2003;16(2):163–7.CrossRefPubMed
36.
go back to reference Charmaz K. Constructing grounded theory. 2nd ed. Los Angeles: Sage; 2014. Charmaz K. Constructing grounded theory. 2nd ed. Los Angeles: Sage; 2014.
37.
go back to reference Bryman A. Social research methods. Oxford: Oxford University Press; 2001. Bryman A. Social research methods. Oxford: Oxford University Press; 2001.
Metadata
Title
Dementia and Physical Activity (DAPA) - an exercise intervention to improve cognition in people with mild to moderate dementia: study protocol for a randomized controlled trial
Authors
Nicky Atherton
Chris Bridle
Deborah Brown
Helen Collins
Sukhdeep Dosanjh
Frances Griffiths
Susie Hennings
Kamran Khan
Ranjit Lall
Samantha Lyle
Rupert McShane
Dipesh Mistry
Vivien Nichols
Stavros Petrou
Bart Sheehan
Anne-Marie Slowther
Margaret Thorogood
Emma Withers
Peter Zeh
Sarah E. Lamb
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Trials / Issue 1/2016
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-016-1288-2

Other articles of this Issue 1/2016

Trials 1/2016 Go to the issue